Oncotelic Therapeutics Inc
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment of orphan oncology indications. It develops antisense and small molecule injectable drugs for the treatment of cancer. The company is also developing OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; OT-101, an antisense against TGF-ß2, w… Read more
Oncotelic Therapeutics Inc (OTLC) - Total Liabilities
Latest total liabilities as of September 2025: $20.08 Million USD
Based on the latest financial reports, Oncotelic Therapeutics Inc (OTLC) has total liabilities worth $20.08 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Oncotelic Therapeutics Inc - Total Liabilities Trend (2017–2024)
This chart illustrates how Oncotelic Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Oncotelic Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Oncotelic Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
The Ruby Mills Limited
NSE:RUBYMILLS
|
India | ₹4.75 Billion |
|
Trimitra Prawara Goldland Tbk Pt
JK:ATAP
|
Indonesia | Rp27.06 Billion |
|
Precise Biometrics AB (publ)
PINK:PRBCF
|
USA | $57.89 Million |
|
KPM TECH Co. Ltd
KQ:042040
|
Korea | ₩80.11 Billion |
|
Korea SE Corp
KQ:101670
|
Korea | ₩16.53 Billion |
|
S.A.L. Steel Limited
NSE:SALSTEEL
|
India | ₹2.67 Billion |
|
Champion Technology Holdings Ltd
PINK:CPIHF
|
USA | $192.90 Million |
|
FM Global Logistics Holdings Bhd
KLSE:7210
|
Malaysia | RM439.04 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Oncotelic Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.08 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.71 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oncotelic Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oncotelic Therapeutics Inc (2017–2024)
The table below shows the annual total liabilities of Oncotelic Therapeutics Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $19.20 Million | +4.33% |
| 2023-12-31 | $18.40 Million | +8.75% |
| 2022-12-31 | $16.92 Million | +9.50% |
| 2021-12-31 | $15.45 Million | +38.21% |
| 2020-12-31 | $11.18 Million | +64.86% |
| 2019-12-31 | $6.78 Million | +484.25% |
| 2018-12-31 | $1.16 Million | -29.59% |
| 2017-12-31 | $1.65 Million | -- |